The first clinically used AAS was testosterone which was discovered in 1935 and first approved for medical use in 1939. Although adverse effects in clinical studies have been infrequent and mild, SARMs can cause elevated liver enzymes, reduction of HDL cholesterol levels, and hypothalamic–pituitary–gonadal axis (HPG axis) suppression, among other side effects. SARMs have been investigated in human studies for the treatment of osteoporosis, cachexia (wasting syndrome), benign prostatic hyperplasia, stress urinary incontinence, and breast cancer. Can be used concurrently to support joint and soft tissue health during training. It does not contribute to HPTA suppression, making it a common addition to MK-2866 cycles targeting body recomposition or cutting goals. This combination can help maintain natural testosterone levels during and after a SARM cycle. Enclomiphene is frequently used as a mini-PCT or on-cycle support with MK-2866 to mitigate testosterone suppression. At these doses, ostarine provides subtle but real improvements in lean mass retention during cutting and modest anabolic effects during maintenance. The critical difference between SARMs and traditional anabolic steroids is selectivity. Selective androgen receptor modulators occupy a complicated position in the natty plus framework. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats. Additionally, RAD-140 can help reduce body fat while preserving lean muscle tissue. The dystrophin gene is located in the X chromosome and a number of its mutations cause truncated proteins that manifest clinically in the form of muscular dystrophy. With wide-spread use of corticosteroids to combat inflammation and allergies, even children are susceptible to corticosteroid-induced muscle wasting. These results support the potential utilization of signaling pathways available in a tissue microenvironment to promote maximal stimulation of the AR by various ligands. We demonstrated that the SARMs and DHT utilize distinct signaling pathways to promote their genomic and non-genomic effects. In addition to the nuclear AR, AR is also thought to be located at the plasma membrane to mediate rapid non-genomic effects. This suggests that each ligand uniquely influences distinct pathways depending on cell and tissue type to mediate its pharmacologic and physiological response (74). Testosterone signals through inhibition of p38 MAPK, Notch-1, Notch-2 and Jagged-1 signaling pathways in macrophages, but utilize PI3K-Akt pathway in bone cells (71–73). The drug was then successfully repurposed as a treatment for breast cancer where it was found to act as a full antagonist in breast tissue. In addition, 7α-alkyl substitution of testosterone (for example trestolone) has also been reported to increase its anabolic effects. In 1950, nandrolone (19-nortestosterone) was first synthesized, which is sometimes considered a SARM due to greater tissue selectivity than testosterone. The combination supports lean mass accrual through complementary mechanisms without additive HPTA suppression, as MK-677 does not affect the androgen axis. "More research needs to be done to know more about SARMs’ effects and their long-term effects, but the preliminary research has raised a number of concerns," Dr. Sanyal shares. In truth, though, SARMs may be more harmful than we initially thought because they could cause widespread complications for your body. Examples of SARMs include ostarine (Enobosarm, MK 2866), andarine (S4), ligandrol (LGD-4033), LGD-3033, TT-701, RAD140 (Testolone) RAD150, and S23. Teens are targeted on social media with marketing promoting use of SARMs to increase muscle and athletic performance. The "overdose" risk is more about taking high doses for an extended time period for body building or performance enhancement. Long-term effects may include risk of heart attack or stroke, permanent liver damage, and increased risk of tendon rupture. Short-term effects include acute liver injury, increased blood pressure and heart rate, chest pain, psychological effects (such as mood swings, psychosis, irritability, anxiety), sleep disturbance, fatigue, acne, and hair loss). Preclinical studies have demonstrated the effectiveness of RAD-140 in promoting muscle growth and fat loss. RAD-140 has shown promising results in preclinical studies, suggesting its potential as a therapeutic agent for various conditions, including muscle wasting disorders and age-related muscle loss . Due to its muscle-preserving and regenerative properties, LGD-4033 may support rehabilitation processes, particularly in scenarios involving muscle atrophy or prolonged inactivity. While insights into AR structure and differential coregulator recruitment offer theoretical avenues for achieving enhanced tissue selectivity, robust evidence linking these mechanisms to meaningful clinical outcomes is still lacking. Despite decades of research and development, SARMs have yet to fulfill the promise of providing truly tissue-selective effects. This hepatotoxicity is likely linked to increased activation of the AR in hepatic tissue and may be an unavoidable consequence of orally bioavailable androgens administered at sufficiently high doses (85). Future research should assess whether lower, less virilizing doses of such nonaromatizable androgens can match SARMs like enobosarm in both efficacy and safety. Indeed, historically, androgens such as testosterone propionate, methenolone and fluoxymesterone demonstrated tumor regression in up to 30% of patients with advanced disease. These findings support the notion that nongenomic pathways may also provide a potential mechanism for tissue selectivity, although its clinical relevance remains unclear.
